CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 103 enrolled
Drug / intervention
Fentanyl D-transdrug
Likely dose
Fentanyl D-trans 12.5 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01060124
NCT01060124Phase 4Completed
CompareCT.gov

Use of Durogesic D-TRANS in Cancer Pain Patients With Inadequately Controlled Pain Relief From Weak Opioids

Janssen Korea, Ltd., Korea·interventional·Posted Feb 2, 2010·Updated Apr 29, 2014

In Brief

A Phase 4 clinical trial evaluating Fentanyl D-trans for Pain; Cancer. Completed, enrolled 103 participants.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl D-Trans (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the skin) treatment in cancer participants of Korea with inadequately controlled pain by non-narcotic analgesics (drug used to control pain) and participant's satisfaction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain; Cancer
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2, 2010
Enrollment StartApr 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.4 years ago

Interventions

Fentanyl D-transdrug

Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.